The Cooper Companies, Inc. (NASDAQ:COO) Shares Sold by Mirador Capital Partners LP

Mirador Capital Partners LP decreased its stake in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 3.3% during the fourth quarter, HoldingsChannel reports. The firm owned 13,360 shares of the medical device company’s stock after selling 451 shares during the quarter. Mirador Capital Partners LP’s holdings in Cooper Companies were worth $1,228,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also bought and sold shares of the company. Ashton Thomas Securities LLC acquired a new position in Cooper Companies during the 3rd quarter valued at approximately $25,000. Covestor Ltd boosted its holdings in Cooper Companies by 144.9% during the third quarter. Covestor Ltd now owns 338 shares of the medical device company’s stock worth $37,000 after buying an additional 200 shares in the last quarter. Brown Brothers Harriman & Co. boosted its holdings in Cooper Companies by 191.0% during the third quarter. Brown Brothers Harriman & Co. now owns 419 shares of the medical device company’s stock worth $46,000 after buying an additional 275 shares in the last quarter. Friedenthal Financial purchased a new stake in Cooper Companies during the third quarter worth $50,000. Finally, Cromwell Holdings LLC purchased a new stake in Cooper Companies during the third quarter worth $52,000. Institutional investors and hedge funds own 24.39% of the company’s stock.

Cooper Companies Price Performance

Shares of COO opened at $91.00 on Thursday. The Cooper Companies, Inc. has a 1-year low of $84.76 and a 1-year high of $112.38. The stock has a market cap of $18.16 billion, a PE ratio of 46.67, a P/E/G ratio of 2.29 and a beta of 0.99. The firm has a 50-day simple moving average of $96.98 and a two-hundred day simple moving average of $98.89. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.91 and a quick ratio of 1.12.

Cooper Companies (NASDAQ:COO) last announced its quarterly earnings results on Thursday, December 5th. The medical device company reported $1.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.00 by $0.04. The business had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1.03 billion. Cooper Companies had a net margin of 10.07% and a return on equity of 9.38%. The business’s revenue for the quarter was up 9.8% on a year-over-year basis. During the same period last year, the business earned $0.87 earnings per share. As a group, analysts forecast that The Cooper Companies, Inc. will post 3.98 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on COO shares. Morgan Stanley lowered their price target on shares of Cooper Companies from $104.00 to $102.00 and set an “equal weight” rating on the stock in a report on Friday, December 6th. Needham & Company LLC reaffirmed a “hold” rating on shares of Cooper Companies in a report on Friday, December 6th. StockNews.com downgraded shares of Cooper Companies from a “buy” rating to a “hold” rating in a report on Wednesday, December 11th. Citigroup decreased their price target on shares of Cooper Companies from $116.00 to $115.00 and set a “buy” rating on the stock in a research note on Friday, December 6th. Finally, Wells Fargo & Company raised their price target on shares of Cooper Companies from $115.00 to $118.00 and gave the stock an “overweight” rating in a research note on Friday, December 6th. Four research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, Cooper Companies currently has a consensus rating of “Moderate Buy” and a consensus target price of $117.00.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.